

7th January 2026

(1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001	(2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5 th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051
Scrip Code: 500087	
Scrip Code: CIPLA EQ	
(3) SOCIETE DE LA BOURSE DE Luxembourg Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg	

Dear Sir/Madam,

Sub: Intimation under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Clarification on USFDA inspectional observations in Form 483 on Pharmathen International S.A. ("Pharmathen")

While the Company was in the process of making relevant clarification under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), it received a communication from Stock Exchanges seeking clarification on the media reports published and displayed across various mainstream media on US Food and Drug Administration (USFDA) inspectional observations in Form 483 on Pharmathen International S.A. (Pharmathen). In this regard, we wish to clarify that Pharmathen is our supply partner, manufacturing Lanreotide Injection for Cipla USA Inc., a wholly owned subsidiary of the Company. As per media reports, based on the Form 483 that became public on 7th January 2026, USFDA conducted an inspection at the manufacturing facility of Pharmathen, located at Rodopi, Greece, from 10th November 2025 to 21st November 2025. Following the inspection, Pharmathen received nine (9) inspectional observations.

Currently, the Company is evaluating the impact of the above event and will keep the Stock Exchanges informed of any update that may have a material impact, in accordance with the applicable regulatory requirements.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

**Rajendra Chopra
Company Secretary**

Prepared by: Chirag Hotchandani

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380